example 20 [WO2010128058]   

GtoPdb Ligand ID: 7853

Compound class: Synthetic organic
Comment: This compound is a BACE2 inhibitor developed by Roche, and is example 20 (out of 130) in patent WO2010128058 [1]. See also BACE2 patent review [2].
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 113.57
Molecular weight 372.11
XLogP 0.47
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES Clc1cnc(nc1)C(=O)Nc1cccc(c1)C1(C)CC(=O)N(C(=N1)N)C
Isomeric SMILES Clc1cnc(nc1)C(=O)Nc1cccc(c1)[C@]1(C)CC(=O)N(C(=N1)N)C
InChI InChI=1S/C17H17ClN6O2/c1-17(7-13(25)24(2)16(19)23-17)10-4-3-5-12(6-10)22-15(26)14-20-8-11(18)9-21-14/h3-6,8-9H,7H2,1-2H3,(H2,19,23)(H,22,26)/t17-/m0/s1
InChI Key VZUGBLTVBZJZOE-KRWDZBQOSA-N
References
1. Banner D et.al. (2010)
Dihydropyrimidinones for use as BACE2 inhibitors.
Patent number: WO2010128058. Assignee: Roche. Priority date: 31/10/2014. Publication date: 11/11/2010.
2. Southan C. (2013)
BACE2 as a new diabetes target: a patent review (2010 - 2012).
Expert Opin Ther Pat, 23 (5): 649-63. [PMID:23506624]